A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial.

Karol M PencinaArthur L BurnettThomas W StorerWen GuoZhuoying LiAdam S KibelGrace HuangMichelle BlouinDonna L BerryShehzad BasariaShalender Bhasin

Published in: The Journal of clinical endocrinology and metabolism (2021)

Administration of OPK-88004 was safe and not associated with PSA recurrence in androgen-deficient men who had undergone radical prostatectomy for organ-confined prostate cancer. OPK-88004 increased lean body mass and decreased fat mass but did not improve sexual symptoms or physical performance.

Keyphrases

prostate cancer
radical prostatectomy
mental health
physical activity
adipose tissue
young adults
middle aged
fatty acid
sleep quality
bone mineral density
depressive symptoms
wild type
postmenopausal women
benign prostatic hyperplasia